ANZCTR search results

The AMMEND study is a 3-month randomised control trial testing the effect of a Mediterranean diet (MD) on the symptoms of depression in young men. Participants will be randomly allocated to either the MD group or the control group, which consists of a social support “befriending” protocol, via a computer-generated block randomisation sequence. At the baseline appointment participants will complete a number of questionnaires and baseline measurements which will be recorded in the Case Report Form, including the Becks Depression Inventory depression scale and a short Dietary Screener Questionnaire (DSQ). Participants will have scheduled follow up appointments at 6 weeks and 12 weeks. Participants in the MD group will complete Diet History Forms to check levels of adherence to the diet and will be scored against the MD Adherence Score. The main outcome measure will be any changes to the BDI depression scale results. At the conclusion of the trial, participants in the MD group will complete a short, electronic, self-administered survey assessing their experiences and perceived benefits and challenges of continuing to follow a Mediterranean diet long term.

The research project is testing a potential new treatment for psoriasis (an inflammatory skin condition) called IMU-935. Before a new medicine can be approved for use in humans, it is necessary to confirm that it is safe and effective. This is done by carrying out clinical research studies such as this one. The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of IMU-935. The pharmacokinetics (PK) of IMU-935 in humans will also be determined. PK testing involves taking blood and urine samples to measure how much of the drug gets into the blood stream, and how long the body takes to get rid of it. When testing for PK, the sample will also be tested for metabolites (breakdown products) of IMU-935.

The purpose of this study is to determine if shared decision making involving the patient, medical team and their support person will be of benefit to a patient in order to identify what is really important in their life. This initially involves approximately a 15 minute telephone conversation talking about the study and what to expect at the multidisciplinary shared decision making meeting. If an inpatient, a bedside conversation will occur to discuss surgical risks and benefits and the next steps. The study centres around informed decisions about their surgery and how they would like to be cared for. Who is it for? You may be eligible for this study if you are older than 65 or older than 45 (if Aboriginal or Torres Strait Islander) and undergoing Major General or Vascular Elective or Semi-urgent surgery. Study details Patients in this study will be randomly assigned to either the control group (standard treatment) or the intervention group. Participants in the intervention group will be involved in a 'shared decision making' team meeting, involving relevant medical professionals and support persons of the patient. Part of involvement in the study will include a variety of questionnaires about surgery decision making and quality of life. It is hoped that this research will help determine how comfortable patients feel about making decision about their healthcare and also assist the medical community in developing strategies for shared decision making.

The purpose of the present study is to evaluate a family-oriented, cognitive behavioural intervention relative to treatment as usual for the treatment of anxiety with children and adolescents meeting diagnostic criteria for an anxiety disorder in a real world clinical setting (the Mater Day Program), The study will compare 2 experimental conditions, namely (1) treatment as usual at the Mater Day Program; and (2) treatment as usual plus an anxiety intervention (consisting of a child-focused program and a parent-focused program). It is hypothesised that the second condition will be significantly more effective in terms of children's diagnostic status; children's self-reported anxiety and depression; overall levels of functional impairment; and parental reports of their child's anxiety. Given the limited number of studies examining the outcomes of family-oriented CBT interventions for anxiety relative to treatment as usual in child and youth mental health settings, along with the paucity of research involving young people with complex and comorbid mental health diagnoses, this study aims to contribute novel information to the current research base.

Food addiction is an emerging area of research. We are interested in developing a novel intervention for those with addictive eating behaviours in Australia. This project will determine if a new personality targeted brief intervention (3 month) targeting in food addiction reduces addictive eating behaviors, improves dietary intake and improves quality of life . The intervention will be delivered via telehealth/phone

Insomnia is a common disorder managed in Australian general practice. Insomnia can be effectively treated with online cognitive and behavioural therapy for insomnia (CBTi), which leads to long-lasting insomnia improvements. We aim to provide Australian GPs with access to an online CBTi program (Sleepio) to treat insomnia and reduce dependence on sleeping pills over time. It is hypothesised that patients referred to this trial of Sleepio will experience improved insomnia symptoms, and reduced sleeping pill use over time.

Diet remains a cornerstone of type 1 diabetes (T1D) management, with carbohydrate intake having the greatest impact on insulin requirements and blood glucose fluctuations. However, there is limited scientific evidence comparing the effect(s) of different levels of carbohydrate intake on T1D management. A T1D outpatient centre in Perth WA has been actively implementing carbohydrate-focused diet interventions, including low-carbohydrate diets, for T1D. This presents an opportunity to conduct a chart review to better understand the effect(s) of varying levels of carbohydrate on T1D management outcomes, and to identify and describe effective dietary approaches for this clinical population. We expect that low-carbohydrate diets (<130 g/day) will lead to improvements in T1D management due to reduced error rates in calculating exogenous insulin requirements.

Our team will develop and test an online forum, MS JobSeek, led by employed peers with multiple sclerosis and overseen by a health psychologist. The peers share their work experiences and help to motivate and encourage persons with MS to explore work and study options. This group coaching and mentoring is supplemented with educational material to help users better understand the current job market. To maximise reach and quality of access we will deliver this targeted support and mentoring via the internet. We will examine whether MS JobSeek is effective in supporting return-to-work progression for persons with relapsing remitting or progressive multiple sclerosis using a rigorous scientific study design. The findings will help to generate new evidence on how job-seekers with multiple sclerosis engage with, and respond to, peer mentoring. We also hope to provide a framework for how peer support services might be run and optimised in vocational care.

ENDOR combination therapy is a natural alternative to steroid use, in the treatment of eczema and psoriasis. ENDOR Dermatitis Care Capsules contain multivitamins and other natural anti-inflammatory ingredients such as curcumin and ENDOR 3.5 cream is a soothing, moisturizing cream. This clinical trial will assess the effectiveness and safety of ENDOR Combination Therapy (ENDOR 3.5 cream and ENDOR Dermatitis Care Capsules) in treating moderate atopic dermatitis or psoriasis. A total of 60 participants will be recruited, and will use ENDOR Combination Therapy for sixty days. During the study, site personnel will assess their skin conditions, take progress photographs and administer questionnaires to assess quality of life. 20% of participants will be allocated to the placebo arm, and will be receiving dummy treatment. These patients will be offered the opportunity to trial ENDOR Combination Therapy at the end of the study if interested.

This pilot trial seeks to investigate the adherence rates and efficacy of an internet-delivered for repetitive negative thinking immediately following treatment and at 1-month follow-up.